HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist.

Abstract
Passive amyloid-β (Aβ) vaccination has shown significant effects on amyloid pathology in pre-depositing amyloidprotein precursor (AβPP) mice but the results in older mice are inconsistent. A therapeutic effect of LXR and RXR agonists consisting of improved memory deficits and Aβ pathology has been demonstrated in different Alzheimer's disease (AD) mouse models. Here, we report the effect of a combination of N-terminal Aβ antibody and synthetic LXR agonist T0901317 (T0) on AD-like phenotype of APP23 mice. To examine the therapeutic potential of this combination, the treatment of mice started at 11 months of age, when amyloid phenotype in this model is fully developed, and continued for 50 days. We show that Aβ immunization with or without LXR agonist restored the performance of APP23 transgenic mice in two behavior paradigms without affecting the existing amyloid plaques. Importantly, we did not observe an increase of brain microhemorrhage which is considered a significant side effect of Aβ vaccination. Target engagement was confirmed by increased Abca1 and ApoE protein level as well as increased ApoE lipidation in soluble brain extract. In interstitial fluid obtained by microdialysis, we demonstrate that immunization and T0 significantly reduced Aβ levels, indicating an increased Aβ clearance. We found no interaction between the immunotherapy and T0, suggesting no synergism, at least with these doses. The results of our study demonstrate that anti-Aβ treatments can ameliorate cognitive deficits in AβPP mice with advanced AD-like phenotype in conjunction with a decrease of Aβ in brain interstitium and increase of ApoE lipidation without affecting the existing amyloid plaques.
AuthorsNicholas F Fitz, Emilie L Castranio, Alexis Y Carter, Ravindra Kodali, Iliya Lefterov, Radosveta Koldamova
JournalJournal of Alzheimer's disease : JAD (J Alzheimers Dis) Vol. 41 Issue 2 Pg. 535-49 ( 2014) ISSN: 1875-8908 [Electronic] Netherlands
PMID24643138 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • ABCA1 protein, mouse
  • ATP Binding Cassette Transporter 1
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Amyloidogenic Proteins
  • Antibodies, Monoclonal
  • Apolipoproteins E
  • Hydrocarbons, Fluorinated
  • Nootropic Agents
  • Sulfonamides
  • T0901317
Topics
  • ATP Binding Cassette Transporter 1 (metabolism)
  • Alzheimer Disease (therapy)
  • Amyloid beta-Peptides (metabolism)
  • Amyloid beta-Protein Precursor (genetics)
  • Amyloidogenic Proteins (immunology)
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Apolipoproteins E (metabolism)
  • Brain (drug effects, pathology, physiopathology)
  • Combined Modality Therapy
  • Conditioning, Psychological (drug effects, physiology)
  • Disease Models, Animal
  • Fear (drug effects, physiology)
  • Female
  • Hydrocarbons, Fluorinated (therapeutic use)
  • Immunization, Passive
  • Male
  • Maze Learning (drug effects, physiology)
  • Memory Disorders (pathology, physiopathology, therapy)
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Nootropic Agents (therapeutic use)
  • Random Allocation
  • Sulfonamides (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: